CSS
KALV

Cubist Systematic Strategies’s KalVista Pharmaceuticals KALV Stock Holding History

Cubist Systematic Strategies’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,772
Closed -$181K – 4007
2023
Q4 		$181K Buy
+14,772
New +$134K ﹤0.01% 3037
2022
Q4 		– Sell
-11,627
Closed -$169K – 4417
2022
Q3 		$169K Sell
11,627
-38,887
-77% -$544K ﹤0.01% 3839
2022
Q2 		$497K Buy
+50,514
New +$557K ﹤0.01% 3066
2022
Q1 		– Sell
-16,982
Closed -$225K – 3662
2021
Q4 		$225K Buy
+16,982
New +$270K ﹤0.01% 2967
2019
Q4 		– Sell
-782
Closed -$9K – 2483
2019
Q3 		$9K Sell
782
-1,122
-59% -$18.1K ﹤0.01% 2148
2019
Q2 		$42K Buy
+1,904
New +$44.7K ﹤0.01% 2341

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Cubist Systematic Strategies's KALV Position: Q1 2024 in Review

Cubist Systematic Strategies sold out of KalVista Pharmaceuticals (KALV) in Q1 2024, closing a stake of 14,772 shares — an estimated $181K sold.

Cubist Systematic Strategies first reported a position in KALV in Q2 2019 and held it in 6 quarters. The position peaked at $497K in Q2 2022. 128 funds tracked by Wall St. Rank hold KALV as of Q1 2024.

  • Cubist Systematic Strategies reported no remaining KalVista Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 14,772 KalVista Pharmaceuticals shares in Q1 2024, an estimated $181K.
  • Cubist Systematic Strategies first reported a position in KalVista Pharmaceuticals in Q2 2019 and held it in 6 quarters.
  • Cubist Systematic Strategies's KalVista Pharmaceuticals position peaked at $497K in Q2 2022.
  • 128 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2024.

Based on Cubist Systematic Strategies's 13F filing for Q1 2024, filed 15 May 2024.